RecruitingPhase 2Drug trialSingle Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon CancersThis is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.